Inspire Medical Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inspire Medical Systems, Inc. - INSP

Inspire Medical’s outlook has collapsed, with legal and operational risks now front and center.

What the company is saying

Inspire Medical Systems, Inc. is communicating that its Inspire V device launch has been severely delayed due to a combination of operational failures and technical setbacks. The company frames these issues as previously undisclosed, citing incomplete training, contracting, and onboarding at many centers, as well as software updates for claims processing that were not implemented until early July. The announcement emphasizes the drastic reduction in 2025 earnings guidance—slashed by more than 80% from $2.20–$2.30 per share to $0.40–$0.50 per share—making this the central message to investors. The company also acknowledges excess inventory and poor demand for the Inspire V device, but provides no quantitative detail on these operational problems. Legal troubles are highlighted, with mention of a securities class action lawsuit alleging failure to disclose material information, and the ongoing investigation by Kahn Swick & Foti, LLC (KSF). The tone is defensive and factual, with little attempt to soften the negative news or offer reassurances about future prospects. Notable individuals involved include Charles C. Foti, Jr., Esq., a former Attorney General of Louisiana and partner at KSF, and Lewis Kahn, Managing Partner, whose roles lend legal gravitas but do not directly impact Inspire Medical’s operations or prospects. The communication style is terse and legalistic, focusing on compliance and disclosure rather than growth or opportunity. Overall, the narrative is one of damage control, with the company forced to admit to significant operational and financial failings while under legal scrutiny.

What the data suggests

The only concrete financial data disclosed is the revised 2025 earnings guidance, which has been slashed by more than 80%, from a previous range of $2.20–$2.30 per share to just $0.40–$0.50 per share. This represents a catastrophic reduction in projected profitability and signals a major deterioration in the company’s financial trajectory. No other financial metrics—such as revenue, cash flow, or balance sheet strength—are provided, making it impossible to assess the full scope of the company’s financial health or to compare performance across periods. The operational issues cited, including incomplete training at many centers and delayed software updates, are not quantified, leaving investors in the dark about the scale and duration of these problems. The gap between what is claimed and what is evidenced is significant: while the company admits to broad operational failures and excess inventory, it provides no supporting numbers or timelines for resolution. There is no indication that prior targets or guidance have been met; in fact, the drastic guidance cut implies severe underperformance. The quality of disclosure is poor, with key metrics missing and no transparency on the underlying drivers of the earnings collapse. An independent analyst would conclude that the company is in a state of operational and financial crisis, with little visibility into when or how it might recover.

Analysis

The announcement is factual and negative in tone, focusing on operational delays, excess inventory, and a drastic reduction in earnings guidance for 2025. There is no promotional or exaggerated language; instead, the narrative centers on the company's failure to meet prior assurances and the resulting legal and financial consequences. The only forward-looking claims are the revised earnings guidance and references to an 'elongated timeframe,' both of which are grounded in disclosed setbacks rather than aspirational projections. No large capital outlay or promises of future benefits are discussed, and the announcement lacks any attempt to inflate the company's prospects. The gap between narrative and evidence is minimal, as the negative developments are supported by the disclosed reduction in earnings guidance.

Risk flags

• ●Operational risk is acute, as the company admits that many centers failed to complete required training, contracting, and onboarding for the Inspire V device. This undermines the company’s ability to generate revenue from its core product and suggests systemic execution failures.
• ●Financial risk is severe, with 2025 earnings guidance slashed by more than 80%. Such a dramatic reduction in projected profitability signals that the company’s business model may be fundamentally impaired, at least in the near term.
• ●Disclosure risk is high, as the company only revealed these operational and technical issues after previously assuring investors that all prerequisites for launch had been met. This pattern raises concerns about management’s transparency and reliability.
• ●Legal risk is material, with a securities class action lawsuit alleging failure to disclose material information and an ongoing investigation into potential breaches of fiduciary duty. Legal proceedings can result in significant financial penalties, reputational damage, and management distraction.
• ●Data quality risk is present, as the announcement lacks key financial and operational metrics such as revenue, cash flow, inventory levels, or demand figures. This lack of transparency makes it difficult for investors to assess the true extent of the company’s problems.
• ●Execution risk is elevated, given that the company must resolve multiple complex issues—training, contracting, onboarding, and software updates—across a distributed network of centers. The absence of a clear timeline or plan increases the likelihood of further delays or setbacks.
• ●Forward-looking risk is significant, as the majority of the company’s narrative now centers on an 'elongated timeframe' for recovery without any concrete milestones or evidence that these issues are being addressed effectively.
• ●Reputational risk is heightened by the involvement of high-profile legal figures such as Charles C. Foti, Jr., Esq., and the public nature of the class action lawsuit. While their participation signals the seriousness of the allegations, it does not guarantee any particular outcome for shareholders.

Bottom line

For investors, this announcement is a clear signal that Inspire Medical Systems, Inc. is facing a crisis on multiple fronts. The company’s core product launch has been derailed by operational failures, and the financial impact is immediate and severe, with 2025 earnings guidance cut by more than 80%. The lack of detail on how or when these issues will be resolved leaves investors with little basis for optimism. The involvement of a top-ranked securities law firm and high-profile legal professionals underscores the seriousness of the legal risks, but their participation does not guarantee a favorable outcome for shareholders or any recovery of value. To change this assessment, the company would need to provide detailed disclosures on operational fixes, updated timelines, and comprehensive financial metrics—including revenue, cash flow, and inventory levels. Key metrics to watch in the next reporting period include any updates on the Inspire V device rollout, progress on resolving training and software issues, and revised guidance or commentary on demand and inventory. Given the current information, this announcement should be weighted heavily in investment decisions as a strong negative signal; it is not actionable for a positive investment thesis and warrants close monitoring for further deterioration or signs of stabilization. The single most important takeaway is that Inspire Medical’s operational and financial credibility is now in question, and investors should demand much greater transparency before considering any exposure.

Announcement summary

(NYSE: INSP) Inspire Medical Systems, Inc. disclosed in August of 2025 that the launch of its Inspire V device faced an "elongated timeframe" due to previously undisclosed issues, including incomplete training, contracting, and onboarding at many centers, and software updates for claims submissions and processing not taking effect until early July. The company reported that excess inventory caused poor demand for the Inspire V device. As a result, Inspire Medical Systems, Inc. slashed its 2025 earnings guidance by more than 80%, from $2.20 to $2.30 per share to $0.40 to $0.50 per share. The company and certain executives were subsequently sued in a securities class action lawsuit for allegedly failing to disclose material information in violation of federal securities laws. The case was transferred from the United States District Court for the Southern District of New York to the District of Minnesota and remains ongoing. Kahn Swick & Foti, LLC (KSF) continues its investigation into whether Inspire's officers and/or directors breached their fiduciary duties or violated state or federal laws. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

Disagree with this article?